Upstream Bio, Inc.-Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

Upstream Bio, Inc.(UPB) Seeking Alpha·2024-12-16 18:03

Company Overview - Upstream Bio, Inc. (NASDAQ: UPB) completed its IPO in October 2024, raising approximately $293 million [2] Investment Positioning - The company is leveraging a unique approach in the biotech sector, positioning itself favorably for future success [2]